SENTÉ Announces Issuance of a New United States Patent For Heparan Sulfate

San Diego, Calif., Oct. 17, 2016 — SENTÉ, a privately held specialty aesthetics company pioneering the development of differentiated medical grade skincare products based on the science of glycosaminoglycan’s, today announced that the company has received a new patent grant, Process For The Purification Of Heparan Sulfate And Use Thereof In Cosmetological And Dermatological Preparations (U.S. Patent No. 9,4330,099) by the United States Patent and Trademark Office (USPTO). The company’s patent estate has now produced patents in Europe and the United States, further strengthening its ability to distribute innovative skin care products worldwide.

“The issuance of this patent is a major milestone for the company and comes at a time when we are gaining significant traction” said Laurent Combredet, Chief Executive Officer. “This further solidifies our IP position and adds to our vision of becoming a leading aesthetics company dedicated to pioneering glycosaminoglycan science.”

“Our focus is to remain dedicated to the development of products based on rigorous science and clinical research” said Faheem Hasnain, Chairman of the Board of Directors. “This patent grant allows us to continue developing innovative and market disrupting technologies in the US and abroad”.

About SENTÉ:

SENTÉ is a privately held specialty aesthetics company leveraging its expertise and foundation in biotechnology to deliver novel, science-based skin care products. SENTÉ is a recognized leader in the development of innovative and targeted medical skincare products based on glycosaminoglycans. Founded in 2007 and based in San Diego, California, further information may be found at https://sentelabs.com/. SENTÉ products are available through its exclusive network of physicians and medically supervised spas.

SENTÉ Press Contact:

Creative Media Marketing
sente@cmmpr.com
(212) 979-8884